CES2 Expression Assessment for Ester-Prodrug Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face variability in success due to drug resistance and poor absorption of chemotherapeutic agents, particularly in biliary tract cancer, where diagnosis and prediction of treatment success are challenging due to heterogeneous CES2 expression in tumors and adjacent tissues.
Innovation Solution
An in-vitro diagnostic method assessing CES2 expression in tumor and adjacent tissues to determine patient susceptibility and response to ester-prodrugs, such as CAP7.1, which is converted by Carboxyl esterase 2 (CES2) to its active form, enabling targeted treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ester prodrugs are used to improve bioavailability and absorption, then therapeutic efficacy is improved, but treatment success varies due to heterogeneous CES2 expression in tumors and adjacent tissues
Solution Approach 1:
The patent performs preliminary diagnostic assessment of CES2 expression in tumor and adjacent tissues before initiating ester prodrug treatment. This advance evaluation allows clinicians to predict which patients will respond well to ester prodrugs and plan appropriate treatment strategies beforehand, avoiding treatment failure due to heterogeneous CES2 expression.
Solution Approach 2:
The patent recognizes that CES2 expression varies locally between tumor tissues and adjacent normal tissues. By assessing CES2 expression specifically in tumor samples and comparing it with adjacent tissues, the diagnostic method identifies local variations in enzyme activity that determine prodrug conversion efficiency and treatment response.
2Measurement precision
If CES2 expression is assessed in tumor samples to predict treatment response, then treatment success prediction is improved, but diagnostic complexity increases
Solution Approach 1:
The patent extracts and evaluates specific CES2 expression data from tumor tissue samples as a standalone diagnostic marker. By focusing on measuring CES2 expression levels in tumor biopsies and comparing them with adjacent tissues, the method isolates the critical predictive information needed for treatment decision-making without requiring complex comprehensive tumor profiling.
3Quantity of substance
If ester prodrugs are administered to cancer patients, then drug bioavailability is improved, but not all patients convert prodrug to active form with same efficiency
Solution Approach 1:
The patent implements a feedback mechanism where CES2 expression levels in tumor tissue are measured and used to guide treatment decisions. Patients with high CES2 expression in tumor tissue are identified as good candidates for ester prodrug treatment, while those with low or heterogeneous expression are directed to alternative therapies, ensuring that prodrug administration is matched to patient-specific enzyme capacity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively predicts treatment success and bioavailability of ester-prodrugs by identifying CES2 expression levels, ensuring drug accumulation in tumor tissues and improving therapeutic outcomes for biliary tract and colorectal cancer patients.
Implementation Method 1
Once absorbed, ester prodrugs undergo hydrolysis to generate active drugs under the action of the esterase
Data Source
Figure 1A~1B
Figure 2
Figure 3A~4B
AI summary
The present invention pertains to a diagnostic and therapeutic method for assessing whether a patient is susceptible to the treatment of an ester-prodrug. The methods of the invention include the analysis of carboxyelesterase 2 (CES2)-expression in tumor samples as a predictive value for the assessment of treatment success with an ester-prodrug of a chemotherapeutic agent. Alternatively, the invention provides methods involving the analysis of the urinary ratio of the prodrug and the active therapeutic as another predictive value for assessing treatment susceptibility.